Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unecritinib in Relapsed/Refractory ALK+ ALCL
NCT04306887Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of unecritinib in anaplastic large cell lymphoma (ALCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate at 18 months. Status: unknown.
02
Drugs
unecritinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT04306887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306887.